You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,129,912


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,129,912
Title: Polyethylene glycol-protein compositions which reduce the antigenic display of red blood cells
Abstract:The present invention provides a composition of matter, comprising a red blood cell coated a polymeric mixture of polyethylene glycol and albumin. Also provided is a method of blocking blood group antigens on the surface of a red blood cell, comprising the step of contacting said cell with a pharmacologically effective concentration of the composition of the present invention.
Inventor(s): Hortin; Glen L. (North Potomac, MD), Huang; Shu T. (Birmingham, AL)
Assignee: UAB Research Foundation (Birmingham, AL)
Application Number:09/160,013
Patent Claims:1. A composition of matter, comprising a red blood cell coated with a cross-linked or branched polyethylene glycol and albumin.

2. The composition of claim 1, wherein said branched polyethylene glycol is an arm polyethylene glycol.

3. The composition of claim 2, wherein said arm polyethylene glycol is a 4 arm polyethylene glycol.

4. The composition of claim 3, wherein said arm polyethylene glycol is 4 arm propionyl-N-hydroxysuccinimide-methoxypolyethylene glycol.

5. The composition of claim 1, wherein the concentration of said polyethylene glycol is from about 0.5% to about 1%.

6. The composition of claim 1, wherein the concentration of said albumin is from about 1.25% to about 10%.

7. The composition of claim 1, wherein said albumin is human albumin.

8. The composition of claim 1, wherein the cell is coated with cross-linked or branched polyethylene glycol and albumin at least one time.

9. A method of blocking blood group antigens on the surface of a red blood cell, comprising the step of coating said cell with a pharmacologically effective concentration of a cross-linked or branched polyethylene glycol and albumin.

10. The method of claim 9, wherein the concentration of said polyethylene glycol is from about 0.5% to about 1%.

11. The method of claim 9, wherein the concentration of said albumin is from about 1.25% to about 10%.

12. The method of claim 9, wherein said albumin is human albumin.

13. A composition of matter, comprising a red blood cell coated with a cross-linked or branched polyethylene glycol and branched polyethylene glycol amine.

14. A composition of matter, comprising a red blood cell coated with a cross-linked or branched polyethylene glycol and a compound containing multiple reaction sites which form a cross-linked matrix with activated esters of polyethylene glycol.

15. A composition of matter, comprising a cell coated with a cross-linked or branched polyethylene glycol and a protein.

16. The composition of claim 15, wherein said cell is a red blood cell.

17. The composition of claim 15, wherein said protein is albumin.

18. The composition of claim 15, wherein said polyethylene glycol is a branched polyethylene glycol.

19. The composition of claim 15, wherein said protein contains multiple reaction sites which form a cross-linked matrix with of polyethylene glycol.

Details for Patent 6,129,912

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Grifols Therapeutics Llc ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 albumin (human) For Injection 101138 10/21/1942 ⤷  Try a Trial 2017-09-26
Baxalta Us Inc. BUMINATE, FLEXBUMIN albumin (human) Injection 101452 03/03/1954 ⤷  Try a Trial 2017-09-26
Csl Behring Ag ALBURX albumin (human) Injection 102366 07/23/1976 ⤷  Try a Trial 2017-09-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.